Chiasma Looks Ahead To First Approval With "Revolutionary" Technology Opportunity
This article was originally published in The Pink Sheet Daily
Anticipating an April 15 user fee date for oral ocreotide for acromegaly, Chiasma thinks its platform technology to make peptides orally available can offer substantial opportunities for therapeutic optionality.
You may also be interested in...
Office of Prescription Drug Promotion seemed to expand its focus in issuing 11 letters last year.
Former senior advisor to President Trump warns that failure to reform drug pricing practices has seriously handicapped prospects for reimbursing cell and gene therapy under existing US payer programs.
A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.